Item 9 Labs Corp
OTC:INLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (12.1), the stock would be worth $-0 (2 994% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.4 | $0 |
0%
|
| Industry Average | 12.1 | $-0 |
-2 994%
|
| Country Average | 19.6 | $-0 |
-4 796%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Item 9 Labs Corp
OTC:INLB
|
701.8 USD | -0.4 | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
870.6B USD | 30.4 | 42.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.4B USD | 21.2 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 12.9 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 22.6 | 28.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 15.9 | 19.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
279.4B USD | 11.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.4 | 10.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 10.1 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 8.8 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Item 9 Labs Corp
Glance View
Item 9 Labs Corp. is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The company is headquartered in Phoenix, Arizona and currently employs 103 full-time employees. The company went IPO on 2011-11-03. The firm produces cannabis and cannabis-related products and offers approximately 75 active cannabis strains and more than 150 differentiated cannabis vape products as well as premium concentrates and Orion vape technologies. The firm's Item 9 Labs brand specializes in select products and user experience across several cannabis categories. The firm also offers a dispensary franchise model through the national Unity Rd. retail brand. Item 9 Labs cultivates elevated mainstream cannabis flower, vape cartridges, concentrates and Apollo & Orion vape technologies. The Company’s products are available to consumers through licensed dispensaries in Arizona. Its products are carried in more than 70 dispensaries throughout the state of Arizona.
